STOCK TITAN
  1. Home
  2. News
  3. PBYI

Puma Biotechnology Inc - PBYI STOCK NEWS

Welcome to our dedicated news page for Puma Biotechnology (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Puma Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Puma Biotechnology's position in the market.

News
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Rhea-AI Summary
Puma Biotechnology, Inc. (NASDAQ: PBYI) will host a conference call to discuss its first quarter 2024 financial results on May 2, 2024. The call will be accessible via phone or webcast, with a replay available on the company's website. Investors and analysts can participate to learn about the latest financial performance and strategic updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Puma Biotechnology, Inc. granted an inducement restricted stock unit award of 7,500 shares of common stock to a new non-executive employee. The award vests over three years, with gradual vesting periods, as part of the 2017 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
-
News
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) receives FDA notification to proceed with the clinical development of alisertib for HER2-negative, hormone receptor-positive metastatic breast cancer. The Phase II ALISCA-Breast1 trial will investigate alisertib in combination with endocrine treatment, targeting patients previously treated with CDK 4/6 inhibitors. The trial aims to identify optimal dosing, biomarker evaluation, and efficacy endpoints to potentially enhance alisertib's efficacy. Puma plans to initiate the trial in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.19%
Tags
none
News
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Puma Biotechnology (PBYI) reported positive financial results for Q4 and full year 2023, with net income of $12.3 million for Q4 and $21.6 million for the full year. Product revenue was $53.2 million for Q4 and $203.1 million for the year. Non-GAAP adjusted net income was $14.8 million for Q4 and $31.8 million for the year. Cash, cash equivalents, and marketable securities stood at $96.0 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
earnings
-
News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Puma Biotechnology, Inc. granted an inducement restricted stock unit award to a new non-executive employee, covering 7,500 shares of Puma common stock. The award vests over three years, with one-third of the shares vesting on the first anniversary of the award's commencement date. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
News
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) CEO Alan H. Auerbach to attend TD Cowen's 44th Annual Health Care Conference in Boston. Auerbach will participate in a Breast & Lung Cancer Corporate Panel Discussion on March 6, 2024, at 9:10 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.83%
Tags
conferences
News
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) will host a conference call to discuss its fourth quarter and full year 2023 financial results on February 29, 2024. The call will provide insights into the company's performance and future outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences earnings
-
News
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) commences ALISertib in CAncer Phase II trial for small cell lung cancer patients who have progressed on previous treatments. The trial aims to evaluate alisertib monotherapy's efficacy with primary and secondary endpoints focusing on response rates, survival, and biomarker analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
clinical trial
-
News
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) CEO Alan H. Auerbach to present at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024. Replay available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.55%
Tags
conferences
News
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer. The trial will evaluate alisertib in combination with endocrine treatment and is expected to initiate in the second half of 2024. The primary efficacy endpoints will include objective response rate, duration of response, disease control rate, and progression-free survival. The Company plans to engage with global regulatory agencies for the design of a pivotal Phase III trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
clinical trial
Stock PBYI logo
Puma Biotechnology Inc

Nasdaq:PBYI

PBYI Rankings

#3571 Ranked by Market Cap
#1266 Ranked by Stock Gains
N/A Ranked by Dividends

PBYI Stock Data

254.05M
29.40M
15.12%
66.91%
6.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Los Angeles

About PBYI

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.